ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Time for India to be firm with drugmakers rather than deregulate

Lax stance risks opportunity for 'friend-shoring' to serve Western nations

| India
Employees pack boxes containing vials of Covishield coronavirus vaccine at the Serum Institute of India in Pune in November 2021: New Delhi should seek to amend the constitution and consolidate drug regulation at a national level.    © AP

Akhil Ramesh is a research fellow at the Pacific Forum, a foreign policy research institute based in Honolulu, Hawaii.

At a time when the U.S. and European nations are becoming anxious about the dependence of their supply chains on China for the production of medicines and drugs, India's vast pharmaceutical industry should be just the cure.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more